

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Brent IVERSON *et al.*

Serial No.: 09/813,444

Filed: March 20, 2001

For: DIRECTED EVOLUTION OF ENZYMES  
AND ANTIBODIES

Group Art Unit: 1641

Examiner: Pensee T. Do

Atty. Dkt. No.: MXGN:005USC2

Confirmation No.: 3269

**CERTIFICATE OF ELECTRONIC TRANSMISSION**

I hereby certify that this correspondence is being  
electronically filed with the United States Patent and  
Trademark Office via EFS-Web on the date below:

April 25, 2008

Date

Steven L. Highlander

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully  
requested that this Supplemental Information Disclosure Statement be entered and the documents  
listed on attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Supplemental Information Disclosure  
Statement is not to be construed as a representation that a search has been made, and is not to be  
construed to be an admission that the information cited is, or is considered to be, material to  
patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed. If an appropriate payment has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/MXGN:005USC2.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

  
Steven L. Highlander  
Reg. No. 37,942  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: April 25, 2008